Similarly, an investigation into the potential therapeutic effects of CD38-specific nanobody-based CAR (Nb-CARs) revealed that Nb-CAR-NK-92 cells might induce cytotoxicity against primary patient-derived CD38-expressing myeloma cells [117]. The gene discussed is CD38; the disease is plasma cell myeloma.